Confirmatory Studies For Rare Diseases Shouldn’t Need To Start Before Accelerated Approval, Stakeholders Argue
A blanket mandate to start confirmatory trials when accelerated approval is granted could force significant investment in surrogate endpoints that are not accepted. • Source: Shutterstock
